Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.350-2.650 for the period, compared to the consensus earnings per share estimate of 2.540. The company issued revenue guidance of $16.8 billion-$17.4 billion, compared to the consensus revenue estimate of $17.1 billion. Teva Pharmaceutical Industries also updated its Q1 2025 guidance to 0.520-0.520 EPS.

Teva Pharmaceutical Industries Trading Down 2.8 %

TEVA stock opened at $15.06 on Friday. The company has a market capitalization of $17.07 billion, a PE ratio of -10.38, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries has a 12 month low of $12.51 and a 12 month high of $22.80. The firm’s 50-day moving average is $17.21 and its 200 day moving average is $18.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Analyst Ratings Changes

TEVA has been the subject of several recent analyst reports. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Bank of America dropped their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. StockNews.com cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Finally, UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.